Слайд 1
Lecture 20.
Steroid hormones
The adrenal cortex is divided
into three zones that synthesize various steroids from cholesterol and
secrete them.
The outer zona glomerulosa produces mineralocorticoids (for example, Aldosterone) which are responsible for regulated primarily by the renin-angiotensin system.
The middle zona fasciculata synthesizes glucocorticoids (for example, Cortisol) which are concerned with normal metabolism and resistance to stress.
The inner zona reticularis secretes adrenal androgens.
Слайд 2
Secretion by the two inner zones, and to some extend,
the outer zone, is controlled by pituitary Corticotropin, which is
released in response to the hypothalamic Corticotropin-releasing hormone. Glucocorticoids serve as feedback inhibitors of Corticotropin and Corticotropin-releasing factor secretion.
Слайд 3
Mechanism of action
The adrenocorticoids bind to specific
intracellular cytoplasmic receptors in target tissues.
The receptor-hormone
complex then translocates into the nucleus where it acts as a transcrition factor to turn genes on or off, depending on the tissue.
This mechanism requires time to produce an effect. There are other glucocorticoid effects, such as their requirement for catecholamine – mediated dilation of vascular and bronchial musculature or lipolysis, whose effects are immediate.
Слайд 4Glucocorticoids (GCs)
1. Short acting (T1/2
– 36 hrs.): Prednizolon
3. Long acting (T1/2>36 hrs): Triamcinolone, Betamethasone
They
can use as therapeutic agents in a variety of disorders.
Слайд 5
The major pharmacodynamic effects of GCs
1. Promote normal intermediary metabolism.
GCs
favor gluconeogenesis by both increasing amino acid uptake by the
liver and kidney and elevating activities of gluconeogenic enzymes.
GCs stimulate protein catabolism (except in the liver) and lipolysis, thereby providing the building blocks and energy needed for glucose synthesis.
Слайд 6
2. Increase resistance to stress
By raising plasma glucose levels, GCs provide the body with the energy it requires to combat stress caused, for example, by trauma, fright, infection, bleeding, or debilitating disease.
Слайд 7
3. Alter blood cell levels in plasma.
GCs cause a decrease in eosinophils, basophils, monocytes and lymphocytes. In contrast, they increase the blood levels of hemoglobin, erythrocytes, platelets and polymorphonuclear leukocytes (this property is important in the treatment of leukemia).
Слайд 8
4. Anti-inflammatory action.
The most important
therapeutic property of the GCs is their ability to dramatically
reduce the inflammatory response and to suppress immunity.
The exact mechanism is complex and incompletely understood.
However, it is know that the lowering and inhibition of peripheral lymphocytes and macrophages play a role.
Also involved is the indirect inhibition of phospholipase A2 (due to the steroid mediated elevation of lipocortin), which blocks the release of arachidonic acid - the precursor of the prostaglandins and leukotrienes, from membrane-bound phospholipid.
Слайд 9
Affect other components of the endocrine
system.
Feedback inhibition of Corticotropin production by
elevated GCs causes inhibition of further glucocorticoid synthesis as well as thyroid stimulating hormone production, whereas growth hormone production is increased.
Слайд 10
Effects on other systems
These are mostly associated with the adverse effects of
the hormones.
High doses of GCs stimulate gastric acid and pepsin production and may exacerbate ulcers.
Effects on the central nervous system that influence mental status have been identified.
Chronic glucocorticoid therapy can cause severe bone loss. Myopathy leads patients to complain of weakness.
Слайд 11Therapeutic uses of GCs
Replacement therapy for primary adrenocortical insufficiency (Addison’s
disease). This disease is caused by adrenal cortex dysfunction. Hydrocortisone
is given to correct the deficiency.
Replacement therapy for secondary adrenocortical insufficiency. This deficiencies are caused by a defect either in CRF (Corticotropin-releasing factor) production by the hypothalamus or Corticotropin production by the pituitary. Hydrocortisone is also used for these deficiencies.
Слайд 12
Diagnosis of Cushing’s syndrome. This syndrome is caused by a
hypersecretion of GCs that is due to either excessive release
of Corticotropin by the anterior pituitary or to an adrenal tumor. The Dexamethasone suppression test is used to diagnose the cause of an individual’s case of Cushing’s syndrome. This synthetic glucocorticoid suppresses Cortisol release in individuals with pituitary-dependent Cushing’s syndrome, but it does not suppress glucocorticoid release from adrenal tumors.
Слайд 13
Relief of inflammatory symptoms. GCs reduce the manifestation of inflammations
(for example, rheumatoid and osteoarthritic inflammations, inflammatory conditions of the
skin), including the redness, swelling, heat and tenderness that are commonly present at the inflammatory site.
Слайд 14
Treatment of allergies. GCs are usefull in the treatment of
the symptoms of drug, serum and transfusion allergic reactions, bronchial
asthma and allergic rhinitis. Betamethasone, Triamcinolone, Prednizolone are the most effective.
Autoimmune diseases.
Organ transplantation.
Limphatic leukemia
Слайд 15Adverse effects of GCs:
osteoporosis
peptic ulceration
glucosuria (hyperglycemia)
increased risk of infection
increased
appetite
hypertension
edema
euphoria
psychoses
Слайд 19Mineralocorticoids
Desoxycorticosterone acetate (DOCA)
Fludrocortisone
Aldosterone
They have only mineralocorticoid activity:
increase renal excretion of Ca++ and K+;
decrease renal excretion
of Na+ and water.
Слайд 20
Adverse effects of Mineralocorticoides includes only:
hypokalemia
edema
sodium retention
(without hyperglycaemia, osteoporosis, euphoria).
Слайд 21
Fludrocortisone
A potent mineralocorticoid having some glucocorticoid activity
as well, orally active, used for:
replacement therapy in Addison’s disease;
congenital
adrenal hyperplasia;
idiopathic postural hypotension.